Nifty
Sensex
:
:
11987.65
40648.47
-11.45 (-0.10%)
-3.17 (-0.01%)

Pharmaceuticals & Drugs

Rating :
46/99  (View)

BSE: 532296 | NSE: GLENMARK

353.70
-5.65 (-1.57%)
21-Nov-2019 | 11:59AM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  358.00
  •  358.65
  •  349.45
  •  359.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2319208
  •  8203.04
  •  705.90
  •  267.25

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 10,134.07
  • 15.77
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 13,644.97
  • 0.56%
  • 1.72

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.58%
  • 0.93%
  • 9.73%
  • FII
  • DII
  • Others
  • 3%
  • 4.31%
  • 35.45%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.80
  • 8.11
  • 2.81

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.85
  • 5.48
  • -4.88

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.04
  • 34.58
  • -5.86

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.23
  • 24.07
  • 18.57

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.22
  • 5.46
  • 3.52

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.11
  • 15.03
  • 11.51

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Net Sales
2,815.04
2,581.33
9.05%
2,322.88
2,165.62
7.26%
2,563.47
2,279.82
12.44%
2,555.05
2,203.66
15.95%
Expenses
2,364.63
2,141.23
10.43%
1,980.97
1,818.73
8.92%
2,199.34
1,952.98
12.61%
2,120.37
1,880.97
12.73%
EBITDA
450.41
440.11
2.34%
341.91
346.88
-1.43%
364.13
326.83
11.41%
434.68
322.69
34.71%
EBIDTM
16.00%
17.05%
14.72%
16.02%
14.20%
14.34%
17.01%
14.64%
Other Income
80.83
139.88
-42.21%
1.67
138.22
-98.79%
39.06
69.55
-43.84%
-109.02
-23.16
-
Interest
89.77
85.13
5.45%
93.02
79.01
17.73%
81.91
74.39
10.11%
88.53
70.47
25.63%
Depreciation
94.16
82.45
14.20%
90.73
79.38
14.30%
80.97
73.53
10.12%
83.10
75.38
10.24%
PBT
347.30
579.59
-40.08%
159.83
326.70
-51.08%
240.31
248.47
-3.28%
154.03
153.67
0.23%
Tax
91.76
165.59
-44.59%
50.55
93.71
-46.06%
78.65
96.84
-18.78%
37.69
48.93
-22.97%
PAT
255.54
414.00
-38.28%
109.28
232.99
-53.10%
161.66
151.63
6.61%
116.34
104.74
11.08%
PATM
9.08%
16.04%
4.70%
10.76%
6.31%
6.65%
4.55%
4.75%
EPS
9.05
14.67
-38.31%
3.87
8.26
-53.15%
5.73
5.37
6.70%
4.12
3.71
11.05%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
10,256.44
9,865.47
9,074.42
9,079.41
7,561.67
6,680.94
5,944.95
4,969.14
4,020.64
2,949.07
2,480.46
Net Sales Growth
11.12%
8.72%
-0.05%
20.07%
13.18%
12.38%
19.64%
23.59%
36.34%
18.89%
 
Cost Of Goods Sold
3,518.99
3,283.71
2,963.32
2,552.03
2,246.58
1,538.25
1,785.62
1,584.70
1,291.00
951.07
784.28
Gross Profit
6,737.45
6,581.76
6,111.10
6,527.39
5,315.09
5,142.69
4,159.33
3,384.44
2,729.65
1,998.00
1,696.18
GP Margin
65.69%
66.72%
67.34%
71.89%
70.29%
76.98%
69.96%
68.11%
67.89%
67.75%
68.38%
Total Expenditure
8,665.31
8,279.67
7,459.05
7,042.71
6,124.52
5,466.62
4,854.17
3,953.86
3,306.28
2,356.82
1,860.89
Power & Fuel Cost
-
165.25
137.47
127.02
120.47
109.11
93.50
80.13
0.00
0.00
31.86
% Of Sales
-
1.68%
1.51%
1.40%
1.59%
1.63%
1.57%
1.61%
0%
0%
1.28%
Employee Cost
-
2,056.07
1,871.84
1,640.81
1,378.19
1,212.61
1,026.15
782.95
628.89
510.17
289.95
% Of Sales
-
20.84%
20.63%
18.07%
18.23%
18.15%
17.26%
15.76%
15.64%
17.30%
11.69%
Manufacturing Exp.
-
725.16
648.59
546.75
956.59
1,323.66
336.59
272.53
54.40
40.76
142.80
% Of Sales
-
7.35%
7.15%
6.02%
12.65%
19.81%
5.66%
5.48%
1.35%
1.38%
5.76%
General & Admin Exp.
-
625.20
526.29
1,022.89
491.20
253.29
859.67
678.94
1,331.99
854.82
268.51
% Of Sales
-
6.34%
5.80%
11.27%
6.50%
3.79%
14.46%
13.66%
33.13%
28.99%
10.83%
Selling & Distn. Exp.
-
1,125.08
996.99
1,064.70
892.67
991.23
524.25
521.00
0.00
0.00
310.32
% Of Sales
-
11.40%
10.99%
11.73%
11.81%
14.84%
8.82%
10.48%
0%
0%
12.51%
Miscellaneous Exp.
-
299.19
314.55
88.52
38.82
38.48
228.40
33.61
0.00
0.00
310.32
% Of Sales
-
3.03%
3.47%
0.97%
0.51%
0.58%
3.84%
0.68%
0%
0%
1.34%
EBITDA
1,591.13
1,585.80
1,615.37
2,036.70
1,437.15
1,214.32
1,090.78
1,015.28
714.36
592.25
619.57
EBITDA Margin
15.51%
16.07%
17.80%
22.43%
19.01%
18.18%
18.35%
20.43%
17.77%
20.08%
24.98%
Other Income
12.54
208.14
91.40
37.37
20.00
6.88
11.48
10.75
18.17
144.41
50.45
Interest
353.23
334.58
285.57
237.32
178.88
190.15
188.59
160.01
146.57
160.46
165.50
Depreciation
348.96
325.90
301.88
264.37
234.28
300.41
216.79
127.01
97.88
94.68
120.61
PBT
901.47
1,133.45
1,119.33
1,572.38
1,043.98
730.63
696.88
739.00
488.09
481.54
383.90
Tax
258.65
375.64
315.46
382.68
300.94
334.07
151.27
110.72
23.78
23.70
52.87
Tax Rate
28.69%
28.88%
28.18%
25.66%
28.83%
61.46%
21.71%
14.98%
4.87%
4.92%
13.77%
PAT
642.82
924.98
803.78
1,108.80
743.23
209.54
542.27
620.03
460.35
453.20
324.47
PAT before Minority Interest
642.72
924.99
803.87
1,108.75
743.04
209.47
545.60
628.29
464.31
457.83
331.03
Minority Interest
-0.10
-0.01
-0.09
0.05
0.19
0.07
-3.33
-8.26
-3.96
-4.63
-6.56
PAT Margin
6.27%
9.38%
8.86%
12.21%
9.83%
3.14%
9.12%
12.48%
11.45%
15.37%
13.08%
PAT Growth
-28.84%
15.08%
-27.51%
49.19%
254.70%
-61.36%
-12.54%
34.69%
1.58%
39.67%
 
Unadjusted EPS
22.77
32.78
28.49
39.29
26.47
7.72
20.01
22.91
17.03
16.78
12.40

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
5,605.18
5,163.48
4,492.52
3,629.64
1,783.49
2,983.28
2,763.03
2,401.63
2,037.24
2,355.23
Share Capital
28.22
28.22
28.22
28.22
27.13
27.12
27.09
27.05
27.03
26.98
Total Reserves
5,566.35
5,124.75
4,462.86
3,599.98
1,756.36
2,956.16
2,735.94
2,374.58
2,010.21
2,328.25
Non-Current Liabilities
2,279.94
2,824.12
3,257.81
1,499.40
2,749.09
1,966.58
1,625.13
1,137.64
519.01
1,940.41
Secured Loans
0.00
0.00
0.00
0.00
0.00
2,428.66
1,920.30
1,312.47
617.07
241.41
Unsecured Loans
3,573.75
4,141.78
4,536.34
2,487.30
2,574.38
0.00
0.00
0.00
0.00
1,627.98
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
14.58
6.90
0.00
Current Liabilities
4,021.09
3,287.89
2,702.68
3,999.25
3,776.71
2,949.17
2,201.39
1,901.74
2,259.06
518.62
Trade Payables
2,220.75
1,869.78
1,743.22
1,940.79
1,948.04
1,362.58
1,036.94
788.83
657.41
379.27
Other Current Liabilities
1,013.21
690.60
509.32
1,137.01
1,264.30
973.31
763.41
414.83
109.80
119.38
Short Term Borrowings
303.02
295.04
187.19
787.42
347.60
353.32
367.82
687.46
1,480.23
0.00
Short Term Provisions
484.11
432.46
262.95
134.03
216.78
259.95
33.22
10.63
11.62
19.97
Total Liabilities
11,905.83
11,275.12
10,452.59
9,127.99
8,309.10
7,912.31
6,613.91
5,466.01
4,842.01
4,827.27
Net Block
3,670.25
3,029.55
2,755.09
2,593.55
2,015.38
2,889.66
2,406.26
2,237.30
2,066.62
1,787.31
Gross Block
6,527.27
5,367.95
4,769.92
4,300.54
3,495.47
3,632.62
2,934.90
2,650.96
2,383.39
2,175.54
Accumulated Depreciation
2,857.01
2,338.39
2,014.83
1,706.99
1,480.09
742.96
528.63
413.66
316.77
388.23
Non Current Assets
5,209.02
4,286.43
3,577.96
3,223.69
2,978.04
3,149.61
2,887.10
2,518.85
2,243.24
2,406.20
Capital Work in Progress
1,398.94
1,121.87
708.11
542.79
477.13
206.24
422.31
248.33
145.70
600.77
Non Current Investment
29.66
14.66
15.69
17.20
17.12
0.00
0.00
0.00
0.00
18.12
Long Term Loans & Adv.
109.57
119.78
98.94
69.99
468.16
33.39
36.52
0.00
0.00
0.00
Other Non Current Assets
0.59
0.56
0.13
0.16
0.27
20.33
22.00
33.23
30.92
0.00
Current Assets
6,696.82
6,988.69
6,874.64
5,904.30
5,331.06
4,762.69
3,726.81
2,947.15
2,598.77
2,421.07
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,252.07
2,030.59
2,139.05
1,567.76
1,269.04
932.88
843.53
787.67
807.01
708.46
Sundry Debtors
2,194.59
2,331.81
2,404.32
2,492.65
2,511.76
2,156.34
1,640.05
1,243.61
1,130.81
1,078.28
Cash & Bank
937.76
1,234.69
1,057.66
857.12
775.88
800.67
607.31
321.92
195.83
107.02
Other Current Assets
1,312.40
810.78
683.39
391.88
774.38
872.81
635.91
593.95
465.11
527.31
Short Term Loans & Adv.
547.18
580.83
590.22
594.89
742.94
768.44
540.03
518.90
322.39
527.31
Net Current Assets
2,675.73
3,700.80
4,171.96
1,905.05
1,554.35
1,813.53
1,525.42
1,045.41
339.71
1,902.45
Total Assets
11,905.84
11,275.12
10,452.60
9,127.99
8,309.10
7,912.30
6,613.91
5,466.00
4,842.01
4,827.27

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,324.17
1,648.05
657.43
344.85
481.68
853.73
647.93
804.39
930.58
352.40
PBT
1,300.63
1,119.33
1,491.43
1,043.98
543.54
696.88
739.00
488.09
481.55
383.90
Adjustment
329.83
571.28
726.56
391.03
522.76
709.78
342.45
484.05
189.65
265.26
Changes in Working Capital
136.34
309.06
-861.51
-611.96
-266.82
-290.07
-268.49
-34.79
353.13
-209.36
Cash after chg. in Working capital
1,766.81
1,999.67
1,356.48
823.05
799.49
1,116.58
812.96
937.35
1,024.34
439.80
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-442.63
-351.61
-699.05
-478.20
-317.81
-262.86
-165.03
-132.96
-93.75
-87.40
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-698.99
-1,013.34
-712.35
-880.17
-540.04
-368.10
-464.06
-277.79
-367.27
-386.91
Net Fixed Assets
455.14
-362.24
-256.09
-286.93
-1,354.84
-112.12
-178.05
-54.88
-40.77
-52.58
Net Investments
-56.07
-1,345.98
-8.28
-198.90
-250.28
-114.91
-211.06
-42.02
-48.33
-755.29
Others
-1,098.06
694.88
-447.98
-394.34
1,065.08
-141.07
-74.95
-180.89
-278.17
420.96
Cash from Financing Activity
-738.74
-468.50
543.15
698.60
199.22
-98.02
195.24
-361.39
-435.61
70.05
Net Cash Inflow / Outflow
-113.56
166.21
488.24
163.27
140.86
387.61
379.11
165.21
127.70
35.54
Opening Cash & Equivalents
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
103.58
71.48
Closing Cash & Equivalent
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
107.02

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
198.27
182.62
159.16
128.59
65.74
109.99
102.01
88.77
75.38
87.28
ROA
7.98%
7.40%
11.33%
8.52%
2.58%
7.51%
10.40%
9.01%
9.47%
7.33%
ROE
17.21%
16.67%
27.31%
27.46%
8.79%
18.99%
24.33%
20.92%
20.85%
16.75%
ROCE
16.47%
14.77%
20.54%
18.53%
12.40%
15.04%
17.67%
14.44%
15.34%
13.88%
Fixed Asset Turnover
1.66
1.80
2.03
1.96
1.90
1.83
1.79
1.60
1.29
1.25
Receivable days
83.73
94.95
97.29
119.39
125.97
115.37
104.99
107.78
136.71
148.42
Inventory Days
79.22
83.59
73.65
67.68
59.42
53.99
59.39
72.38
93.78
97.70
Payable days
97.43
96.28
101.59
117.03
95.22
83.15
68.48
108.47
106.73
68.48
Cash Conversion Cycle
65.53
82.26
69.35
70.04
90.17
86.21
95.91
71.69
123.76
177.63
Total Debt/Equity
0.80
0.90
1.05
1.10
2.13
1.10
1.00
0.93
1.03
0.79
Interest Cover
4.89
4.92
7.28
6.84
3.86
4.70
5.62
4.33
4.00
3.32

News Update


  • Glenmark Pharmaceuticals reports 38% fall in Q2 consolidated net profit
    15th Nov 2019, 15:58 PM

    Total consolidated income of the company increased by 6.42% at Rs 2895.87 crore for Q2FY20

    Read More
  • Glenmark recalling around 2.17 lakh cartons of Estradiol Vaginal inserts in US
    11th Nov 2019, 09:49 AM

    The ongoing voluntary class II recall is on account of a defective delivery system with complaints for the difficulty in pushing the plunger of the applicator

    Read More
  • Glenmark’s arm gets USFDA’s nod for Adapalene and Benzoyl Peroxide Gel
    11th Nov 2019, 08:50 AM

    The Epiduo Gel, 0.1% 2.5% market achieved annual sales of approximately $33.7 million

    Read More
  • Glenmark Pharma’s arm gets USFDA’s approval for Abiraterone Acetate Tablets
    17th Oct 2019, 09:12 AM

    The Zytiga Tablets, 250 mg market achieved annual sales of approximately $794.1 million

    Read More
  • Glenmark gets USFDA’s tentative approval for Dimethyl Fumarate Delayed-Release Capsules
    9th Oct 2019, 09:13 AM

    Dimethyl Fumarate Delayed-Release Capsules is a generic version of Tecfidera Capsules

    Read More
  • Glenmark gets warning letter from USFDA for Baddi facility
    7th Oct 2019, 10:53 AM

    The United States Food and Drug Administration had inspected the facility between April 15 and April 20

    Read More
  • Glenmark gets nod from Russian Ministry of Healthcare to market Montlezir film-coated tablets
    30th Sep 2019, 12:23 PM

    Montlezir is expected to be available in the Russian market in Q3 FY 2019-20

    Read More
  • Glenmark Pharma gets shareholders' nod to raise up to $200 million
    30th Sep 2019, 10:30 AM

    The proposal was approved at the company's annual general meeting held on September 27, 2019

    Read More
  • Glenmark secures position in Dow Jones Sustainability Emerging Markets Index
    26th Sep 2019, 14:01 PM

    The DJSI analyses companies on the corporate economic, environmental and social performance

    Read More
  • Glenmark receives Orphan Drug Designation for GBR 1342
    17th Sep 2019, 09:25 AM

    The candidate is one of five clinical-stage assets in the pipeline of Glenmark’s new innovation company

    Read More
  • Glenmark Pharma’s arm gets USFDA’s final nod for Clobetasol Propionate Foam
    10th Sep 2019, 09:31 AM

    The Olux-E Foam, 0.05% market achieved annual sales of approximately $11.1 million

    Read More
  • Glenmark initiates process of reorganising itself into three different entities
    5th Sep 2019, 11:44 AM

    The company expects the process to be completed in the current fiscal year

    Read More
  • Glenmark Pharma’s arm receives USFDA’s approval for Pimecrolimus Cream
    30th Aug 2019, 09:17 AM

    The Elidel Cream, 1% market achieved annual sales of approximately $198.8 million

    Read More
  • Glenmark Pharma's arm recalling over 31,000 tubes of anti-fungal cream from US market
    26th Aug 2019, 09:46 AM

    Clotrimazole and Betamethasone Dipropionate cream is used on the skin to treat fungal infections of the feet, genitals, inner thighs and buttocks, arms and legs and other body parts

    Read More
  • Glenmark Pharma's arm receives USFDA’s approval for Fulvestrant Injection
    23rd Aug 2019, 09:15 AM

    The Faslodex Injection, 250 mg/5 mL (50 mg/mL) market achieved annual sales of approximately $549.9 million

    Read More
  • Glenmark Pharma gets nod for combination of Remogliflozin and Metformin
    19th Aug 2019, 12:22 PM

    The company will commercialize the combination under the brand names ‘Remo-M’ and ‘Remozen-M’

    Read More
  • Glenmark Pharmaceuticals reports 53% fall in Q1 consolidated net profit
    14th Aug 2019, 10:55 AM

    Total consolidated income of the company increased marginally by 0.90% at Rs 2,324.55 crore for Q1FY20

    Read More
  • Glenmark Pharma - Quarterly Results
    13th Aug 2019, 18:50 PM

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.